Delivery Order SPE2DB20D1004-SPE2DB20FF1B5
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the provision of pharmaceutical products and medical supplies. The contract, valued at $98,562.31, is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA, worth up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver...
- This federal contract award, valued at $2,555.43, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $4,722.50 from the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical care items. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of pharmaceutical products and medical supplies to the U.S. government. Awarded by the Defense Logistics Agency (DLA) Troop Support Medical, the $10,538.79 delivery order falls under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. The IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $94,252.99 delivery order is part of the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies, including...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,044.96 issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract covers the provision of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- The federal contract award is for pharmaceutical and medical supply distribution services provided by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,451.10, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA worth up to $999,999,999.00 that runs through November 2026. The IDC enables Amerisourcebergen to supply a comprehensive range of pharmaceutical products,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., provides pharmaceutical products and medical supplies to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,814.81 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical and medical commodities,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The contract, which runs through November 2026, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for pharmaceutical and medical supply distribution. The $3,575.40 delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies,...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB20FF1B5Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for pharmaceutical and medical supply products. The $1,423.96 delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical and medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The contract award was made through full and open competition without any set-aside designations, reflecting Amerisourcebergen's established position as a key vendor for federal healthcare procurement. Additionally, the company holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 9/11/20 |